Abstract:Introduction: The first human adeno-associated virus (AAV) was originally discovered in 1960s as a contaminant of adenovirus stock preparation and thus it had not been of medical interest. Throughout the last three decades AAV has gained popularity to be used in gene therapy, mainly due to its replicative defectiveness and lack of pathogenicity in human. In addition, its ability to mediate stable and long-term expression in both non-dividing and dividing cells with specific tissue tropism makes AAV one of the most promising candidates for therapeutic gene transfer to treat many inherited as well as non-inherited disorders. Moreover, the use of AAV is not only restricted to overexpression of recombinant transgene, but also to over-express short hairpin RNA and microRNA to knockdown the expression of genes in targeted tissues. Discussion and conclusion: This review is organized into four parts. In the first part of the review, we discuss about the discovery and history of AAV, followed by detailed AAV biology such as virus genome, virus structure and its life cycle. In the second part of the review, the discussion is centred on the molecular mechanisms of AAV and tissue transduction, including receptor recognition and cell binding, endosomal entry, virus uncoating, nuclear entry and genome replication. Advantages and limitations of using AAV as a safe vehicle for gene delivery is also discussed. In the third part of the review, we discuss about the most commonly used AAV serotypes and variants isolated from human and non-human primates, focusing on their diverse tissue tropisms, transduction efficiency, immunological profiles and their applications in animal studies. Final part of the review focuses on the recent progress of in-vivo gene transfer using AAV for inherited and non-inherited diseases in both preclinical and clinical settings with a special emphasis on potential clinical applications of AAV in the field of liver disease.

AAV-mediated gene therapy: Advancing cardiovascular disease treatment

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Adeno-associated virus therapies: Pioneering solutions for human genetic diseases

Adeno-associated virus as a delivery vector for gene therapy of human diseases

Adeno-associated virus vector as a platform for gene therapy delivery

AAV for Gene Therapy in Ocular Diseases: Progress and Prospects

AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges

AAV-Based Targeting Gene Therapy

Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation

Engineering adeno-associated virus vectors for gene therapy

AAV-based in vivo gene therapy for neurological disorders

Adeno-Associated Virus-mediated Gene Therapy for Cardiac Tachyarrhythmia: A Systematic Review and Meta-analysis

rAAV:a Promising Vehicle for Gene Therapy

Generation of targeted adeno-associated virus (AAV) vectors for human gene therapy.

Adeno-Associated Virus (AAV) as a Vector for Gene Therapy

Optimization strategies and advances in the research and development of AAV‐based gene therapy to deliver large transgenes

The clinical landscape for AAV gene therapies

Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy

Current Clinical Applications of In Vivo Gene Therapy with AAVs

The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders

Myocardial infarction creates a critical time window for AAV gene therapy